The pharmaceutical industry must move beyond a business and manufacture to become a beacon of action for the countless lives lost and impacted by the social blight of addiction.
Increasing evidence suggests an interplay between the gut microbiome and nonalcoholic fatty liver disease (NAFLD). The role of the microbiome in the early detection of the condition remains unclear.